Spruce Biosciences Stock Forecast, Price & News

Spruce Biosciences (NASDAQ:SPRB) Frequently Asked Questions

Is Spruce Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Spruce Biosciences stock.
View analyst ratings for Spruce Biosciences or view top-rated stocks.

Are investors shorting Spruce Biosciences?

Spruce Biosciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 1,210,000 shares, an increase of 78.7% from the December 15th total of 677,300 shares. Based on an average trading volume of 3,720,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 17.1% of the company's stock are short sold.
View Spruce Biosciences' Short Interest.

When is Spruce Biosciences' next earnings date?

Spruce Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022.
View our earnings forecast for Spruce Biosciences.

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) announced its earnings results on Monday, November, 15th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08.
View Spruce Biosciences' earnings history.

What price target have analysts set for SPRB?

6 brokers have issued twelve-month price objectives for Spruce Biosciences' stock. Their forecasts range from $5.00 to $20.00. On average, they anticipate Spruce Biosciences' stock price to reach $10.60 in the next twelve months. This suggests a possible upside of 312.5% from the stock's current price.
View analysts' price targets for Spruce Biosciences or view top-rated stocks among Wall Street analysts.

Who are Spruce Biosciences' key executives?

Spruce Biosciences' management team includes the following people:

• Mr. Michael G. Grey, Exec. Chairman (Age 68, Pay $14.85k)
• Mr. Richard A. King M.B.A., CEO & Director (Age 56, Pay $839.55k)
• Mr. Samir M. Gharib CPA, M.B.A., CPA, Chief Financial Officer (Age 39, Pay $454.9k)
• Dr. Rosh Dias, Chief Medical Officer (Age 53, Pay $623.44k)

Who are some of Spruce Biosciences' key competitors?

Some companies that are related to Spruce Biosciences include KemPharm (KMPH), XOMA (XOMA), Sierra Oncology (SRRA), Enochian Biosciences (ENOB), Akouos (AKUS), Gelesis (GLS), Immutep (IMMP), Capstar Special Purpose Acquisition (CPSR), Theratechnologies (THERF), Aeglea BioTherapeutics (AGLE), Werewolf Therapeutics (HOWL), Fortress Biotech (FBIO), Antibe Therapeutics (ATBPD), Aerovate Therapeutics (AVTE) and Harrow Health (HROW).
View all of SPRB's competitors.

When did Spruce Biosciences IPO?

(SPRB) raised $75 million in an IPO on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.

What is Spruce Biosciences' stock symbol?

Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB."

Who are Spruce Biosciences' major shareholders?

Spruce Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Marquette Asset Management LLC (0.17%). Company insiders that own Spruce Biosciences stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest.
View institutional ownership trends for Spruce Biosciences.

Which major investors are buying Spruce Biosciences stock?

SPRB stock was bought by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC. Company insiders that have bought Spruce Biosciences stock in the last two years include Bali Muralidhar, and Venture Fund Iii L Rivervest.
View insider buying and selling activity for Spruce Biosciences or or view top insider-buying stocks.

How do I buy shares of Spruce Biosciences?

Shares of SPRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spruce Biosciences' stock price today?

One share of SPRB stock can currently be purchased for approximately $2.57.

How much money does Spruce Biosciences make?

Spruce Biosciences has a market capitalization of $60.30 million. The company earns $-29.54 million in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Spruce Biosciences have?

Spruce Biosciences employs 17 workers across the globe.

What is Spruce Biosciences' official website?

The official website for Spruce Biosciences is www.sprucebiosciences.com.

How can I contact Spruce Biosciences?

The company can be reached via email at [email protected].